Skip to content
Loading…
Samsung Biologics Co. is seeking to raise about 3 trillion won ($2.2 billion) in a rights offering to fund its acquisition of PolyPeptide Group.
To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.